Clinical Trial Update: Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting on the safety of autologous M2 macrophages for treating non-acute ischemic or hemorrhagic stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Stroke
• Stroke

Drugs mentioned

• Autologous M2 Macrophages (M2 macrophages)

Snippet

Sponsor: Siberian Branch of the Russian Academy of Medical Sciences | Conditions: Ischemic Stroke, Hemorrhagic Stroke | Phase 1 | Status: COMPLETED